XXIIHIGH SIGNALFINANCIAL10-K

XXII experienced a dramatic collapse in gross profit alongside substantial debt reduction and improved cash position, indicating a major operational restructuring.

The near-complete erosion of gross profit suggests either a fundamental shift in business model or severe operational challenges, though this was partially offset by meaningfully reduced net losses. The company's financial position appears more stable with substantially lower debt levels and improved cash reserves, suggesting management may be executing a turnaround strategy focused on financial stabilization over revenue growth.

Comparing 2026-03-26 vs 2025-03-20View on EDGAR →
FINANCIAL ANALYSIS

The company's financial profile underwent dramatic changes, with gross profit collapsing to near-zero levels while net losses were meaningfully reduced from $15.2M to $5.1M. The balance sheet strengthened considerably, with total debt falling by 89% to $708K and cash growing 62% to $7.1M, while total liabilities were cut roughly in half. Operating cash flow improved substantially though remained negative, and the company reduced R&D spending by 39%, suggesting a comprehensive restructuring focused on preserving cash and reducing financial obligations.

FINANCIAL STATEMENT CHANGES
Gross Profit
P&L
-98.4%
$899K→$14K

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Total Debt
Balance Sheet
-89.4%
$6.7M→$708K

Debt reduced 89.4% — deleveraging strengthens balance sheet and reduces financial risk.

Net Income
P&L
+66.7%
-$15.2M→-$5.1M

Net income grew 66.7% — bottom-line growth signals improving overall business health.

Cash & Equivalents
Balance Sheet
+61.7%
$4.4M→$7.1M

Cash position surged 61.7% — strong cash generation or capital raise providing significant financial cushion.

Capital Expenditure
Cash Flow
-56.7%
$141K→$61K

Capex reduced 56.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Assets
Balance Sheet
+53%
$11.5M→$17.6M

Current assets grew 53% — improving short-term liquidity or inventory/receivables build.

Total Liabilities
Balance Sheet
-51.7%
$17.7M→$8.5M

Liabilities reduced 51.7% — deleveraging improves balance sheet strength and financial flexibility.

Operating Cash Flow
Cash Flow
+46.2%
-$14.3M→-$7.7M

Operating cash flow surged 46.2% — exceptional cash generation, highest quality earnings signal.

R&D Expense
P&L
-39.3%
$1.1M→$688K

R&D spending cut 39.3% — could signal cost discipline or concerning reduction in innovation investment.

Current Liabilities
Balance Sheet
-27%
$10.0M→$7.3M

Current liabilities reduced — improved short-term financial position and working capital health.

LANGUAGE CHANGES
NEW — 2026-03-26
PRIOR — 2025-03-20
ADDED
On March 20, 2026, the registrant had 662,023 shares of common stock issued and outstanding.
We may be unsuccessful at commercializing our Reduced Nicotine Content (RNC) tobacco and the VLN brand RNC cigarettes using the reduced exposure claims authorized by the Food and Drug Administration (FDA).
The States or National Association of Attorneys General (NAAG) may not approve our products in certain states which, could have an adverse impact on our results of operations.
Unless the context otherwise requires, references to the Company, 22 nd Century, we, us, and our refer to 22nd Century Group, Inc., a Nevada corporation, and its subsidiaries.
is a tobacco products company that enables cigarette smokers to take control of their consumption of nicotine, the addictive drug in cigarettes.
+7 more — sign up free →
REMOVED
On March 17, 2025, the registrant had 2,369,552 shares of common stock issued and outstanding.
Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of December 31, 2024.
We may be unsuccessful at commercializing our Reduced Nicotine Content (RNC) tobacco and the RNC cigarette brand, VLN , using the reduced exposure claims authorized by the Food and Drug Administration (FDA).
The States or NAAG may not approve our products in certain states which could have an adverse impact on our results of operations.
We are a named defendant in certain litigation matters; if we are unable to resolve these matters favorably, then our business, operating results and financial condition may be adversely affected.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →